Fundraising FoxAlta Partners — 2014 Investments
3 investments dated 2014 · listed companies and verified rows first · show all
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAvoro Capital AdvisorsForesite CapitalOUP (Osage University Partners)Sofinnova Ventures
Biopharma developing HDL-C regulating therapies; listed 2000.
BiotechAnn Arbor, US
Roger S. Newton(Director)inTim M. Mayleben(Executive Officer, Director)
BoardDaniel Janney(Director)Dov A. Goldstein(Director)Nicole Vitullo(Director)inPatrick Enright(Director)in
PartnerDan Janney· led
Co-investorsAisling CapitalArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan PartnersHealthCap+5 more
Kite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells.
BiotechHealthtechSanta Monica, US
Arie S. Belldegrun(Executive Officer, Director)inMargo R. Roberts(Executive Officer)Cynthia Butitta(Executive Officer)inMarc Better(Executive Officer)inRizwana Sproule(Executive Officer)inArie Belldegrun(Founder)
Co-investorsPontifax Venture CapitalVida Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.